118 related articles for article (PubMed ID: 8263156)
21. [(125I)iodo-zacopride: new ligand for the study by autoradiography of central 5-HT3 receptors].
Koscielniak T; Ponchant M; Laporte AM; Guminski Y; Verge D; Hamon M; Gozlan H
C R Acad Sci III; 1990; 311(6):231-7. PubMed ID: 2121314
[TBL] [Abstract][Full Text] [Related]
22. Serotonergic regulation of adrenocortical function.
Lefebvre H; Contesse V; Delarue C; Vaudry H; Kuhn JM
Horm Metab Res; 1998; 30(6-7):398-403. PubMed ID: 9694569
[TBL] [Abstract][Full Text] [Related]
23. Effects of zacopride and BMY25801 (batanopride) on radiation-induced emesis and locomotor behavior in the ferret.
King GL; Landauer MR
J Pharmacol Exp Ther; 1990 Jun; 253(3):1026-33. PubMed ID: 2359014
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of 5-hydroxytryptamine4(5-HT4) receptors positively coupled to adenylate cyclase in adult guinea pig hippocampal membranes: effect of substituted benzamide derivatives.
Bockaert J; Sebben M; Dumuis A
Mol Pharmacol; 1990 Mar; 37(3):408-11. PubMed ID: 2314390
[TBL] [Abstract][Full Text] [Related]
25. Effect of serotonin4 (5-HT4) receptor agonists on aldosterone secretion in idiopathic hyperaldosteronism.
Lefebvre H; Cartier D; Duparc C; Contesse V; Lihrmann I; Delarue C; Vaudry H; Fischmeister R; Kuhn JM
Endocr Res; 2000 Nov; 26(4):583-7. PubMed ID: 11196433
[TBL] [Abstract][Full Text] [Related]
26. Effect of the serotonin 5-HT4 receptor agonist cisapride on aldosterone secretion in corticotropic insufficiency and primary hyperaldosteronism.
Lefebvre H; Dhib M; Godin M; Contesse V; Delarue C; Rieu M; Wolf LM; Vaudry H; Kuhn JM
Neuroendocrinology; 1997 Sep; 66(3):229-33. PubMed ID: 9380281
[TBL] [Abstract][Full Text] [Related]
27. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model.
Barnes NM; Cheng CH; Costall B; Ge J; Kelly ME; Naylor RJ
Eur J Pharmacol; 1992 Jul; 218(1):91-100. PubMed ID: 1356807
[TBL] [Abstract][Full Text] [Related]
28. Central serotonergic stimulation of aldosterone secretion.
Shenker Y; Gross MD; Grekin RJ
J Clin Invest; 1985 Oct; 76(4):1485-90. PubMed ID: 2997280
[TBL] [Abstract][Full Text] [Related]
29. l-Lysine Acts as a Serotonin Type 4 Receptor Antagonist to Counteract In Vitro and In Vivo the Stimulatory Effect of Serotonergic Agents on Aldosterone Secretion in Man.
Duparc C; André C; Ménard J; Godouet-Getti B; Wils J; Cailleux AF; Moreau-Grangé L; Louiset E; Lefebvre H
Horm Metab Res; 2017 Apr; 49(4):269-275. PubMed ID: 28103616
[TBL] [Abstract][Full Text] [Related]
30. Repeated treatment with antidepressant drugs induces subsensitivity to the excitatory effect of 5-HT4 receptor activation in the rat hippocampus.
Bijak M; Tokarski K; Maj J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):14-9. PubMed ID: 9007837
[TBL] [Abstract][Full Text] [Related]
31. Action of serotonin in the medial prefrontal cortex: mediation by serotonin3-like receptors.
Ashby CR; Edwards E; Wang RY
Synapse; 1992 Jan; 10(1):7-15. PubMed ID: 1536032
[TBL] [Abstract][Full Text] [Related]
32. Emesis and defecations induced by the 5-hydroxytryptamine (5-HT3) receptor antagonist zacopride in the ferret.
King GL
J Pharmacol Exp Ther; 1990 Jun; 253(3):1034-41. PubMed ID: 2162943
[TBL] [Abstract][Full Text] [Related]
33. Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells.
Contesse V; Lefebvre H; Lenglet S; Kuhn JM; Delarue C; Vaudry H
Can J Physiol Pharmacol; 2000 Dec; 78(12):967-83. PubMed ID: 11149386
[TBL] [Abstract][Full Text] [Related]
34. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus.
Young R; Glennon RA
Eur J Pharmacol; 1992 Feb; 212(1):117-9. PubMed ID: 1555633
[TBL] [Abstract][Full Text] [Related]
35. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system.
Kidd E; Bouchelet de Vendegies I; Levy JC; Hamon M; Gozlan H
Eur J Pharmacol; 1992 Jan; 211(1):133-6. PubMed ID: 1618262
[TBL] [Abstract][Full Text] [Related]
36. Homologous desensitization of 5-hydroxytryptamine4 receptors in rat esophagus: functional and second messenger studies.
Rondé P; Ansanay H; Dumuis A; Miller R; Bockaert J
J Pharmacol Exp Ther; 1995 Mar; 272(3):977-83. PubMed ID: 7891352
[TBL] [Abstract][Full Text] [Related]
37. Peristalsis evoked by 5-HT and renzapride: evidence for putative 5-HT4 receptor activation.
Craig DA; Clarke DE
Br J Pharmacol; 1991 Mar; 102(3):563-4. PubMed ID: 1364818
[TBL] [Abstract][Full Text] [Related]
38. 5-HT3 receptors mediate inhibition of acetylcholine release in cortical tissue.
Barnes JM; Barnes NM; Costall B; Naylor RJ; Tyers MB
Nature; 1989 Apr; 338(6218):762-3. PubMed ID: 2524005
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological profile of serotonergic receptors in the adrenal gland.
Delarue C; Contesse V; Lefebvre H; Lenglet S; Grumolato L; Kuhn JM; Vaudry H
Endocr Res; 1998; 24(3-4):687-94. PubMed ID: 9888560
[TBL] [Abstract][Full Text] [Related]
40. [3H]zacopride binding to 5-hydroxytryptamine3 sites on partially purified rabbit enteric neuronal membranes.
Gordon JC; Barefoot DS; Sarbin NS; Pinkus LM
J Pharmacol Exp Ther; 1989 Dec; 251(3):962-8. PubMed ID: 2600824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
